A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall confirmed objective response rate (ORR)
From screening until at least 28 days beyond discontinuation of study treatment.
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A6181040
NCT00092001
January 2005
March 2007
Name | Location |
---|---|
Pfizer Investigational Site | Richmond, Virginia 23249 |
Pfizer Investigational Site | Westminster, Maryland 21157 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Asheville, North Carolina 28801 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |